MedTrace Logo

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

NCT02216513 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2015-07-21

No results posted yet for this study

Summary

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Conditions

  • Subarachnoid Hemorrhage

Interventions

DRUG

desferrioxamine (DFO)

DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days

DRUG

placebo

normal saline IV for 4 hours for 5 consecutive days

Sponsors & Collaborators

  • Dr. Jeffrey Thomas Stroke Shield Foundation

    collaborator UNKNOWN

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Farzaneh A Sorond, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-06-30
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02216513 on ClinicalTrials.gov